MX2016013667A - Formulacion liofilizada de factor de crecimiento hepatico (hgf). - Google Patents

Formulacion liofilizada de factor de crecimiento hepatico (hgf).

Info

Publication number
MX2016013667A
MX2016013667A MX2016013667A MX2016013667A MX2016013667A MX 2016013667 A MX2016013667 A MX 2016013667A MX 2016013667 A MX2016013667 A MX 2016013667A MX 2016013667 A MX2016013667 A MX 2016013667A MX 2016013667 A MX2016013667 A MX 2016013667A
Authority
MX
Mexico
Prior art keywords
freeze
dried
growth factor
hepatocyte growth
present
Prior art date
Application number
MX2016013667A
Other languages
English (en)
Inventor
OHORI Ryo
Horie Kanta
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2016013667A publication Critical patent/MX2016013667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

El propósito de la presente invención es proporcionar una preparación liofilizada que tenga una estabilidad al almacenamiento mejorada de factor de crecimiento de hepatofito mejorada en comparación con preparaciones liofilizadas convencionales. La presente invención proporciona una preparación liofilizada, que contiene (1) factor de crecimiento de hepatocito, (2) trehalosa y (3) uno o más compuestos seleccionados del grupo que consiste en arginina, histidina, lisina, meglumina, ácido glutámico, ácido aspártico, prolina, creatina, creatinina, tris (hidroximetil) aminometano y sales farmacéuticamente aceptables de los mismos.
MX2016013667A 2014-04-28 2015-04-24 Formulacion liofilizada de factor de crecimiento hepatico (hgf). MX2016013667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014092888 2014-04-28
PCT/JP2015/062523 WO2015166885A1 (ja) 2014-04-28 2015-04-24 Ｈｇｆ凍結乾燥製剤

Publications (1)

Publication Number Publication Date
MX2016013667A true MX2016013667A (es) 2017-01-23

Family

ID=54358614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013667A MX2016013667A (es) 2014-04-28 2015-04-24 Formulacion liofilizada de factor de crecimiento hepatico (hgf).

Country Status (16)

Country Link
US (1) US11547743B2 (es)
EP (1) EP3138575B1 (es)
JP (1) JP6568846B2 (es)
KR (1) KR102291913B1 (es)
CN (1) CN106456695B (es)
AU (1) AU2015254307B2 (es)
BR (1) BR112016025051A2 (es)
CA (1) CA2947396C (es)
ES (1) ES2887079T3 (es)
IL (1) IL248377B (es)
LT (1) LT3138575T (es)
MX (1) MX2016013667A (es)
RU (1) RU2693472C2 (es)
SG (2) SG11201608583YA (es)
TW (2) TWI674902B (es)
WO (1) WO2015166885A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11548926B2 (en) 2016-03-17 2023-01-10 Eisai R&D Management Co., Ltd. Method for producing an active hepatocyte growth factor (HGF)
KR20240035394A (ko) * 2021-05-14 2024-03-15 클라리스 바이오쎄라퓨틱스, 인코포레이티드 안질환 치료를 위한 성장 인자 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JP2706704B2 (ja) 1989-06-05 1998-01-28 敏一 中村 組換ヒト肝実質細胞増殖因子
JP2577091B2 (ja) 1989-08-11 1997-01-29 三菱化学株式会社 肝実質細胞増殖因子及びそれをコードする遺伝子
JP3036782B2 (ja) 1990-04-03 2000-04-24 三菱化学株式会社 ヒト肝実質細胞増殖因子の生産方法および該因子を産生する形質転換体
JP2777678B2 (ja) 1990-06-11 1998-07-23 敏一 中村 組換ヒト肝実質細胞増殖因子及びその製造方法
JP3072628B2 (ja) 1990-11-19 2000-07-31 敏一 中村 ヒト肝実質細胞増殖因子をコードする染色体ｄｎａ
JP3213985B2 (ja) 1991-10-18 2001-10-02 三菱化学株式会社 新規なタンパク質
JP3232714B2 (ja) 1992-11-20 2001-11-26 三菱化学株式会社 新規なタンパク質およびそれをコードする遺伝子
CA2102463A1 (en) 1992-11-05 1994-05-06 Mitsubishi Chemical Corporation Protein and gene encoding said protein
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
JP2747979B2 (ja) 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
JP2859577B2 (ja) 1996-03-27 1999-02-17 三菱化学株式会社 肝実質細胞増殖因子
JP4463885B2 (ja) 1996-12-05 2010-05-19 敏一 中村 劇症肝炎疾患治療剤
JP2980888B2 (ja) 1998-07-09 1999-11-22 三菱化学株式会社 肝実質細胞増殖因子をコードする遺伝子
ATE359809T1 (de) 1999-05-31 2007-05-15 Mitsubishi Chem Corp Gefriergetrocknete hgf-präparationen
JP4090236B2 (ja) 2000-12-05 2008-05-28 三菱化学株式会社 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法
DE10204792A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
US7432044B2 (en) 2004-07-26 2008-10-07 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activation
US7741096B2 (en) 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
JP5093783B2 (ja) 2006-04-20 2012-12-12 クリングルファーマ株式会社 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質
CA2673260A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
CN102271707B (zh) * 2008-10-29 2015-04-08 阿布林克斯公司 单域抗原结合性分子的制剂
BR112012009245A2 (pt) 2009-10-19 2019-09-24 Genentech Inc ''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
JP2012051822A (ja) 2010-08-31 2012-03-15 Institute Of Physical & Chemical Research 肺癌診断用ポリペプチド、肺癌の検出方法、および治療効果の評価方法
US9272018B2 (en) 2011-04-18 2016-03-01 Kyoto University Acute hepatic insufficiency depressant and method for evaluating drug efficacy thereof
WO2013018851A1 (ja) 2011-08-02 2013-02-07 独立行政法人国立がん研究センター 誘導肝幹細胞から肝分化誘導する方法及び誘導肝前駆細胞
EP2908862B1 (en) 2012-10-20 2018-03-07 Board Of Regents, The University Of Texas System Cancer cell trap
RU2506946C1 (ru) * 2012-11-28 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Технология лиофилизации обогащенной тромбоцитами плазмы с сохранением жизнеспособности факторов tgf pdgf vegf
US20200341014A1 (en) 2016-03-18 2020-10-29 Eisai R&D Management Co., Ltd. PD Marker of Hepatocyte Growth Factor (HGF)
CN106175986B (zh) 2016-07-26 2017-12-01 复旦大学附属中山医院 一种瓣膜夹合器

Also Published As

Publication number Publication date
KR20160146736A (ko) 2016-12-21
RU2019119586A3 (es) 2022-01-25
TW202017588A (zh) 2020-05-16
IL248377A0 (en) 2016-11-30
ES2887079T3 (es) 2021-12-21
KR102291913B1 (ko) 2021-08-23
AU2015254307A1 (en) 2016-11-10
RU2016146121A (ru) 2018-05-28
TWI728409B (zh) 2021-05-21
EP3138575A1 (en) 2017-03-08
BR112016025051A2 (pt) 2018-02-20
RU2016146121A3 (es) 2018-11-28
TWI674902B (zh) 2019-10-21
CN106456695B (zh) 2019-11-12
EP3138575A4 (en) 2018-01-24
JPWO2015166885A1 (ja) 2017-04-20
LT3138575T (lt) 2021-08-25
CN106456695A (zh) 2017-02-22
TW201601747A (zh) 2016-01-16
CA2947396A1 (en) 2015-11-05
IL248377B (en) 2020-04-30
AU2015254307A2 (en) 2016-11-24
US20170189487A1 (en) 2017-07-06
JP6568846B2 (ja) 2019-08-28
AU2015254307B2 (en) 2019-11-07
EP3138575B1 (en) 2021-07-14
WO2015166885A1 (ja) 2015-11-05
CA2947396C (en) 2021-10-19
SG11201608583YA (en) 2016-11-29
SG10201809228RA (en) 2018-11-29
RU2693472C2 (ru) 2019-07-03
RU2019119586A (ru) 2019-07-26
US11547743B2 (en) 2023-01-10

Similar Documents

Publication Publication Date Title
PH12017500838B1 (en) Solution comprising nicotine in unprotonated form and protonated form
TN2017000452A1 (en) Compositions of obeticholic acid and methods of use
MX2018000048A (es) Inhibidores de hpk1 y métodos de uso de los mismos.
EP3892292A3 (en) Stabilized antibody-containing liquid formulations
EA201492214A1 (ru) Ингибиторы вируса гепатита с
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690752A1 (ru) Ингибиторы g12c kras
CY1121326T1 (el) Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες
PH12016501328A1 (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
EA201691139A1 (ru) Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты и полиоксиэтиленовое касторовое масло
NZ741342A (en) Daptomycin formulations and uses thereof
PH12020550703A1 (en) Sulfonamide compounds and use thereof
ES2530423A2 (es) Nuevas formas solidas de inhibidores de la fosfodiesterasa tipo 5
MX2021012939A (es) Formulaciones de factor ix liofilizadas.
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX2016013667A (es) Formulacion liofilizada de factor de crecimiento hepatico (hgf).
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
EA201691741A1 (ru) Фармацевтическая композиция
PH12017501832A1 (en) Stabilized pharmaceutical composition
MX2021014310A (es) Formulaciones de terlipressina.
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
EA201890642A1 (ru) Твердые растворимые составы пирофосфата железа, наборы и способы их применения
WO2017003194A3 (ko) 녹차 아미노산 및 카페인을 포함하는 신경 세포 보호용 조성물
TR201800927A2 (tr) Si̇satrakuryum i̇çeren enjeksi̇yonluk li̇yofi̇li̇ze farmasöti̇k kompozi̇syonlar
EA201891136A1 (ru) Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль

Legal Events

Date Code Title Description
FG Grant or registration